课题基金 / 基金详情

Using LIBRA-seq to identify broadly-reactive influenza antibodies in human respiratory tissues for translation into novel monoclonal therapeutics

Using LIBRA-seq to identify broadly-reactive influenza antibodies in human respiratory tissues for translation into novel monoclonal therapeutics
使用 LIBRA-seq 识别人类呼吸道组织中广泛反应的流感抗体,以转化为新型单克隆疗法
批准号:
473524
负责人:
McGrath Joshua J
金额:
$10.93万
依托单位国家:
加拿大
项目类别:
Fellowship Programs
财政年份:
2022
资助国家:
加拿大
项目状态:
未结题
起止时间:
2022-10-01 至 2025-10-01

项目摘要

项目成果

McGrath Joshua J的其他基金

相似基金

相关文献

中文摘要
翻译
尽管早在90年前就被发现,流感病毒仍然是世界上最危险的呼吸道病原体之一。每年,流行的流感毒株会发生变异,以逃避预先存在的免疫,导致约40万人死亡。此外,独特的菌株
英文摘要
Despite being identified 90 years ago, influenza virus remains one of the most dangerous respiratory pathogens worldwide. Each year, circulating influenza strains mutate to evade pre-existing immunity and kill ~400 000 people. In addition, unique strains
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using LIBRA-seq to identify broadly-reactive influenza antibodies in human respiratory tissues for translation into novel monoclonal therapeutics
海外基金